Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major...
Saved in:
Institution: | Universidad EIA |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artículo de revista |
Language: | English |
Published: |
ELSEVIER
2019-07-13
|
Online Access: | https://repositorio.udes.edu.co/handle/001/5694 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|